Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

August 23, 2017

Primary Completion Date

August 1, 2020

Study Completion Date

October 22, 2020

Conditions
Acute Lymphoblastic Leukemia
Interventions
DRUG

GRASPA

Administration of 1-7 doses of 150 IU/kg IV infusion. (every 2 weeks for a maximum of 4 doses and every 6 weeks for maximum 3 doses).

Trial Locations (23)

2100

Rigshospitalet, Hematological department, Copenhagen

8000

Aahus University hospial, hematological department, Aarhus

8200

Aarhus University hospital, Aarhus

Unknown

Aalborg University Hospital, pediatric department, Aalborg

Rigshospitalet, Child and Adolescent Medicine, Copenhagen

Odense University hospital, pediatric department, Odense

Tallin Childrens Hospital, Tallinn

Tartu University Clinics, Tartu

Childrens Hospital, Helsinki. University Central Hospital, Helsinki

Kuopio University Hospital, Kuopio

University Hospital of Oulu, Oulu

Tampere University Hospital, Tampere

Turku University Hospital, Turku

Vilnius University Children's Hospital, Vilnius

Helse Bergen, Bergen

Oslo Universitetssykehus, Rikshospitalet, Oslo

St Olavs Hospital, Trondheim

Drottning Silvias Barn- och ungdomssjukhus, Gothenburg

Universitetssjukhuset Linköping, Linköping

Skånes Universitets sjukhus, Lund

Astrid Lindgrens Barnsjukhus Karolinska, Stockholm

arn- och Ungdomscentrum Norrlands Universitetssjukhus, Umeå

Akademiska sjukhuset Uppsala, Uppsala

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ERYtech Pharma

INDUSTRY

lead

Birgitte Klug Albertsen

OTHER